Novel electrospun implants of Sunitinib can depress ex-vivo ocular neovascularization
Choroidal neovascularization (CNV) is one of the hallmark symptoms of Wet Age-related Macular Degeneration (wAMD) and Diabetic Retinopathy(DR) which involves formation of neoangiogenic i.e. formation of new abnormal blood vessels emerging from the choroidal blood vessels and protruding through retin...
Saved in:
Published in | British Journal of Pharmacy Vol. 7; no. 2; pp. S1 - S2 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Huddersfield, United Kingdom
University of Huddersfield Press
01.11.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Choroidal neovascularization (CNV) is one of the hallmark symptoms of Wet Age-related Macular Degeneration (wAMD) and Diabetic Retinopathy(DR) which involves formation of neoangiogenic i.e. formation of new abnormal blood vessels emerging from the choroidal blood vessels and protruding through retinal layer. The current management of wAMD involves intravitreal injections of anti-VEGF such as ranibizumab and aflibercept. We hypothesized the delivery of small molecule anti-angiogenesis agent such as Sunitinib by episcleral route could be an effective and less challenging solution for the management of the choroidal neovascularization. In this research, we have fabricated the sunitinib-loaded implants that are able of sustained release of drug and possess improved ocular pharmacokinetics with a non-invasive administration. The novel episcleral implants were fabricated by electrospinning and were test for different physiochemical and well as 'in-vitro' pharmacokinetic properties. Further, these implants were tested for in-vitro biocompatibility and ex-vivo efficacy for estimation of pharmacodynamics properties. |
---|---|
Bibliography: | British Journal of Pharmacy, Vol. 7, No. 2, Nov 2022, S1-S2 Informit, Melbourne (Vic) |
ISSN: | 2058-8356 2058-8356 |
DOI: | 10.5920/bjpharm.1174 |